February 3, 2026 4:53pm

As I wrote this a.m., “They’re lurking, … “uncle algo and his electronic trading dwarfs” are hungry. Cause and effect coming volatility.” From Monday’s positive close.

Right again, it just keeps happening!

News: Ultragenyx Pharmaceutical (RARE +$0.05 or +0.18% to $24.80) new long‑term data from clinical studies evaluating UX111 (rebisufligene etisparvovec), an investigational AAV9 gene therapy for Sanfilippo syndrome Type A (MPS IIIA), a fatal neurodegenerative lysosomal storage disorder. The results demonstrate substantial and durable biomarker improvements and meaningful functional benefits compared with natural history, with consistent and highly statistically significant results across age and disease severity. UX111 was well-tolerated and the safety profile remains favorable.

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

RMi Pre-opening: Brace … https://www.regmedinvestors.com/articles/14294

RMi Finance Note: Sangamo Therapeutics (SGMO) Offering 35.19 M shares priced at $0.4719 … https://www.regmedinvestors.com/articles/14295    

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Tuesday: The Dow closed DOWN -166.67 points or -0.34%, the S&P closed DOWN -58.63 points or -0.84% while the Nasdaq closed DOWN -336.9222 points or -1.43%

  • Theme of the session: rotation

Tuesday’s (my) 40-company covered sector’s advance/decline line opened positive with 28 incliners, 10 decliners and 2 flats, ending with a close negative close of 21 incliners, 18 decliners and 1 flat

The CBOE Fear (VIX) index, Tuesday closed at 17.91, after Monday’s 16.53, Friday’s 17.66, Thursday’s 16.89, Wednesday’s16.40, and last Tuesday’s 16.22

Metrics: Tuesday …

  • The RUT was up +8.21 points or +0.31%,
  • The XLV was down -1.59 points or 1.02%,
  • The NBI was down -3.92points or -0.07%;
  • The XBI was up +0.30 points or +0.24%
  • The IWM was up +0.59 or +0.23%;
  • The IBB was down -0.34 points or -0.20%,
  • The VIX was up +1.57 points or +9.60% at to 17.91

 

Q1/26 February – 1 negative and 1 positive sessions

  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Tuesday Closing UP (10 of 18) 

  • Alnylam Pharmaceuticals (ALNY +$12.69 after Monday’s +$1.05 after Friday’s -$8.73),
  • uniQure NV (QURE +$3.10 after Monday’s +$1.98 after Friday’s -$0.94),
  • Capricor Therapeutics (CAPR +$1.79 after Monday’s +$1.20),
  • Ionis Pharmaceuticals (IONS +$1.52),
  • CRISPR Therapeutics (CRSP +$0.69 after Monday’s +$1.35 after Friday’s -$3.39),
  • BioLife Solutions (BLFS +$0.51),
  • Wave Life Sciences (WVE +$0.27),
  • Dyne Therapeutics (DYN +$0.20 after Monday’s +$0.87 after Friday’s +$0.01)
  • AxoGen (AXGN +$0.19),
  • Vericel (VCEL +$0.16 after Monday’s +$0.96),

Flat (1)

  • Harvard Apparatus RT (OTCQB: HRGN $0.00 (was -$0.11) after Monday’s -$0.10 after Friday’s $0.00)

Tuesday’s Closing DOWN (10 of 21): 

  • IQIA Holdings (IQV -$27.54 after Monday’s +$1.01 after Friday’s -$5.33),
  • Vertex (VRTX -$6.40 after Monday’s +$2.11 after Friday’s -$5.78),
  • Arrowhead Pharmaceuticals (ARWR -$0.86 after Monday’s +$3.67 after Friday’s +$0.21),
  • Lenz Therapeutics (LENZ -$0.77),
  • BioNTech (BNTX -$0.63 after Monday’s -$4.87 after Friday’s -$3.02),
  • Sarepta Therapeutics (SRPT -$0.44),
  • Supernus Therapeutics (SUPN -$0.38 after Monday’s +$0.62),
  • Moderna (MRNA -$0.35 after Monday’s -$1.52 after Friday’s -$2.79),
  • Cellectis SA (CLLS -$0.29),
  • Sangamo Therapeutics (SGMO -$0.1779)

 

The Bottom Line: More of the … WHY

New month of February, a sprint down after a big up …

As indexes DIVED Tuesday following Monday’s UP, still shaking on the AI trading uncertainties as earnings flooded in.

  • The Nasdaq sank it on Tuesday, acting the worst among the falling major indexes as investors sold tech stocks and sought defensive names all-the-while analyzing Q reports.
  • Volume was much higher on both the Nasdaq and NYSE versus Monday. On the Nasdaq exchange, falling stocks topped rising issues by around 9-to-5. On the NYSE, losers outpaced winners slightly.

Some spillage:

  • Pfizer (PFE) reported Q4 results that topped estimates even amid dwindling demand for its Covid products, while reaffirming its modest 2026 guidance that rattled investors in December.
  • Merck (MRK) quashed Q4 expectations on the back of a solid Keytruda beat, but issued lackluster expectations for 2026 as its Gardasil challenges continue. For the year, Merck said it expects to earn an adjusted $5 to $5.15 per share, completely missing the Street's call for $5.27. The company said the guidance includes a one-time charge of $3.65 related to the takeover of Cidara Therapeutics. But the sales outlook also came in short at $65.5 billion to $67 billion. Analysts projected a stronger $67.45 billion, according to FactSet.

Since, the Q4 and FY25 earnings cycle is about to appear beginning 2/5 and 2 more on 2/14

•              2/5 – Arrowhead Pharmaceuticals (ARWR)

•              2/5 – IQVA Holdings (IQV)

•              2/12 – Alnylam Pharmaceuticals (ALNY), Vertex (VRTX)

•              2/13 – Moderna (MRNA)

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering on upsides shook but not rocked the C&GT sector and markets!

•              As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

February – 1st week

  • Tuesday closed negative with 18 incliners, 21 decliners and 1 flat
  • Monday closed positive with 29 incliners, 10 decliners and 1 flat

January – 5th week:

  • 1/30 – Friday closed negative with 6 incliners, 32 decliners and 2 flat
  • 1/29 - Thursday closed positive with 22 incliners, 17 decliners and 1 flat
  • 1/28 - Wednesday closed negative with 4 incliners, 35 decliners and 1 flat
  • 1/27 - Tuesday closed positive with 21 incliners, 19 decliners and 0 flat
  • 1/26 -Monday closed positive with 19 incliners, 18 decliners and 3 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Tuesday: Alnylam Pharmaceuticals (ALNY), uniQure NV (QURE) and Capricor Therapeutics (CAPR)
  • Monday: Arrowhead Pharmaceuticals (ARWR), Vertex (VRTX) and UniQure NV (QURE)
  • Friday: Arrowhead Pharmaceuticals (ARWR), AxoGen (AXGN) and Brainstorm Cell Therapeutics (BCLI)

The worst three (3) in the session: Losers

  • Tuesday: IQIA Holdings (IQV), Vertex (VRTX) and Arrowhead Pharmaceuticals (ARWR)
  • Monday: BioNTech (BNTX), Moderna (MRNA) and Regenxbio (RGNX)
  • Friday: Alnylam Pharmaceuticals (ALNY), IQIA Holdings (IQV) and Vertex (VRTX)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.